AK112 for advanced clear cell kidney cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new drug called AK112 (Yiwoxidan Anti) in people with advanced clear cell kidney cancer who cannot take TKI medications. The goal is to see if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your kidney cancer must be the clear cell type and have spread to other parts of the body.
- You must not have received any previous drug treatment for advanced kidney cancer.
- You must be able to get around (ECOG score of 0 or 1).
- You cannot have had immunotherapy or targeted therapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study uses a special imaging agent called RYZ512 to see how it works in people with advanced clear cell kidney cancer that has spread. Participants will receive RYZ512 and have scans; you may qualify if you can pause certain medications temporarily.
This study looks at genetic (RNA) testing of kidney cancer tissue to help choose the best drug treatment. It may help guide therapy for people with advanced or metastatic clear cell kidney cancer who are starting treatment for the first time.
This study tests a new medicine called AK112 for people with advanced kidney cancer (clear cell type) that has not yet been treated. The goal is to see if this medicine can help shrink or slow the cancer, and to check its safety.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This trial tests a new drug, BMS-986527, for people with advanced kidney cancer that has not responded to standard treatments. The goal is to see if it is safe and if it helps shrink tumors.
This trial tests a new drug, ivonescimab, for people with advanced clear cell kidney cancer that has grown after at least one prior treatment. It may help shrink tumors or slow the cancer's growth.
Hear when a new Metastatic Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.